Back to top
more

Pharma Mar (PHMMF)

(Delayed Data from OTC)

$26.85 USD

26.85
NA

0.00 (0.00%)

Updated Apr 15, 2024 12:19 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for PHMMF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Pharma Mar falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents -99,999 192 239 223 23
Receivables NA 31 60 27 13
Notes Receivable NA 0 0 0 0
Inventories NA 29 12 14 10
Other Current Assets NA 38 38 16 10
Total Current Assets NA 290 349 281 56
Net Property & Equipment NA 33 32 25 25
Investments & Advances NA 53 14 25 2
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 32 33 38 46
Intangibles NA 3 4 4 7
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 414 436 377 140
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable NA 0 0 0 0
Accounts Payable NA 32 35 27 22
Current Portion Long-Term Debt NA 14 14 17 33
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 55 51 63 11
Total Current Liabilities NA 103 102 108 68
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 47 81 106 2
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 27 40 43 59
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 179 225 260 131
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 12 13 13 12
Capital Surplus NA 75 84 81 80
Retained Earnings NA 165 143 48 -78
Other Equity NA 0 0 0 -4
Treasury Stock NA 17 30 25 2
Total Shareholder's Equity NA 235 210 117 8
Total Liabilities & Shareholder's Equity NA 414 436 377 140
Total Common Equity 0 235 210 117 8
Shares Outstanding 18.00 18.00 18.00 18.40 18.40
Book Value Per Share 0.00 13.05 11.69 6.38 0.45

Fiscal Year End for Pharma Mar falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 -99,999 190 -99,999 197
Receivables NA NA 33 NA 26
Notes Receivable NA NA NA NA 0
Inventories NA NA 38 NA 35
Other Current Assets NA NA 23 NA 19
Total Current Assets NA NA 284 NA 276
Net Property & Equipment NA NA 43 NA 33
Investments & Advances NA NA 13 NA 52
Other Non-Current Assets NA NA NA NA 0
Deferred Charges NA NA 34 NA 33
Intangibles NA NA 2 NA 3
Deposits & Other Assets NA NA NA NA 0
Total Assets NA NA 380 NA 401
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA NA NA NA 0
Accounts Payable NA NA 23 NA 23
Current Portion Long-Term Debt NA NA 14 NA 14
Current Portion Capital Leases NA NA NA NA 0
Accrued Expenses NA NA NA NA 0
Income Taxes Payable NA NA NA NA 0
Other Current Liabilities NA NA 55 NA 57
Total Current Liabilities NA NA 94 NA 96
Mortgages NA NA NA NA 0
Deferred Taxes/Income NA NA 30 NA 42
Convertible Debt NA NA NA NA 0
Long-Term Debt NA NA 29 NA 29
Non-Current Capital Leases NA NA NA NA 0
Other Non-Current Liabilities NA 0 NA 0
Minority Interest (Liabilities) NA NA NA NA 0
Total Liabilities NA NA 156 NA 168
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA NA NA NA 0
Common Stock (Par) NA NA 12 NA 12
Capital Surplus NA NA 78 NA 77
Retained Earnings NA NA 162 NA 169
Other Equity NA NA 0 NA 0
Treasury Stock NA NA 27 NA 24
Total Shareholder's Equity NA NA 224 NA 233
Total Liabilities & Shareholder's Equity NA NA 380 NA 401
Total Common Equity 0 0 100,223 0 233
Shares Outstanding NA 18.00 18.00 18.00 18.00
Book Value Per Share 0.00 0.00 5,567.97 0.00 12.94